KRAS Kickers featured at AACR
American Association for Cancer Research (AACR) is the first and largest cancer research organization dedicated to accelerating the...
Search
- Mar 26, 2021
- 3 min
Adagrasib for Patients With Advanced KRAS G12C–Mutated NSCLC
Treatment with the KRAS G12C inhibitor adagrasib showed clinical activity in patients with advanced non–small cell lung cancer (NSCLC)...
- Mar 25, 2021
- 3 min
Second Drug Targeting KRAS G12C Shows Benefit in Mutated Non-Small-Cell Lung Cancer
Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced...
- Mar 11, 2021
- 14 min
Lilly Announces Details of Presentations at 2021 American Association for Cancer Research
Eli Lilly and Company (NYSE: LLY) today announced that data from programs across its oncology portfolio and pipeline will be presented at...
- Mar 11, 2021
- 2 min
Lilly rejoins KRAS race with swipe at Amgen and Mirati, plans 2021 clinical trial
Eli Lilly has rejoined the KRAS race months after toxicity forced it to dump its first candidate. The Big Pharma is set to enter phase 1...
- Mar 6, 2021
- 7 min
The Epic Battle with Cancer's 'Death Star'
David Cox Forty years after the mutant genes that cause the deadliest cancers were discovered, drugs that target them could be approved...
- Feb 5, 2021
- 4 min
How Scientists Shot Down Cancer’s ‘Death Star’
Gina Kolata No drug could touch a quivering protein implicated in a variety of tumors. Then one chemist saw an opening. After 40 years of...
- Jan 25, 2021
- 3 min
Sotorasib Provides Durable Clinical Benefit for Patients with NSCLC and KRAS Mutations
IASLC Exciting New Research to be Presented at International Association for the Study of Lung Cancer World Conference on Lung Cancer’s...
- Jan 19, 2021
- 23 min
The Improbable Targeted Therapy: KRAS as an Emerging Target in Non-Small Cell Lung Cancer
KRAS is a frequent oncogenic driver in solid tumors, including non-small cell lung cancer (NSCLC). It was previously thought to be an...
